Top Markets
#1 Astar Astar +30.03%
#2 Bitway Bitway +21.88%
#3 Hive Hive +17.85%
#4 Cap Cap +12.99%
#5 PondCoin PondCoin +9.50%
#6 Venom Venom +9.09%
#7 Steem Steem +7.81%
#8 stake.link stake.link +7.68%
#9 Clearpool Clearpool +6.95%
#10 Celo Celo +5.42%
Coin of the day
Astar Astar
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rangering i aksjer #170
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Aksjekurs
$519.38
Sist synkronisert: 2026-09-14
Markedsverdi
$131.82B
Endring (1 dag)
0.76%
Endring (1 år)
32.09%
Land
US
Handel Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Antall utestående aksjer for Vertex Pharmaceuticals Incorporated (VRTX)
Antall utestående aksjer per June 2026: 253.90M
Ifølge Vertex Pharmaceuticals Incorporated sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 253.90M. Ved slutten av December 2024 hadde selskapet 257.50M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Vertex Pharmaceuticals Incorporated (VRTX) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -75.51%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 88.62%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 55.97%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -100.00%
BE